Record overview
Status and phase
Status: RECRUITING
Phase: PHASE2
Sponsor: Emory University
Condition: Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
NCT05039073
Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: long_recruitment_duration_signal
Results signal: Low Signal
Operational burden: strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.